K
Klaus Fellermann
Researcher at Robert Bosch Hospital
Publications - 110
Citations - 9294
Klaus Fellermann is an academic researcher from Robert Bosch Hospital. The author has contributed to research in topics: Inflammatory bowel disease & Ulcerative colitis. The author has an hindex of 46, co-authored 110 publications receiving 8705 citations. Previous affiliations of Klaus Fellermann include University of Lübeck & Bosch.
Papers
More filters
Journal ArticleDOI
Reduced Paneth cell α-defensins in ileal Crohn's disease
Jan Wehkamp,Nita H. Salzman,Edith Porter,Edith Porter,Sabine Nuding,Michael Weichenthal,Robert E. Petras,Bo Shen,Elke Schaeffeler,Matthias Schwab,Rose Linzmeier,Ryan W. Feathers,Hiutung Chu,Heriberto Lima,Klaus Fellermann,Tomas Ganz,Eduard F. Stange,Charles L. Bevins +17 more
TL;DR: It is reported that patients with CD of the ileum have reduced antibacterial activity in their intestinal mucosal extracts, and changes in HD5 expression levels, comparable to those observed in CD, had a pronounced impact on the luminal microbiota.
Journal ArticleDOI
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
Jan Wehkamp,Jürgen Harder,Michael Weichenthal,Matthias Schwab,E Schäffeler,Miriam Schlee,Klaus Herrlinger,A. Stallmach,F. Noack,Peter Fritz,Jens-Michael Schröder,Charles L. Bevins,Klaus Fellermann,Eduard F. Stange +13 more
TL;DR: As alpha defensins are important in the mucosal antibacterial barrier, their diminished expression may explain, in part, the bacterial induced mucosal inflammation and ileal involvement of Crohn’s disease, especially in the case of NOD2 mutations.
Journal ArticleDOI
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon.
Klaus Fellermann,Daniel E. Stange,Elke Schaeffeler,Hartmut Schmalzl,Jan Wehkamp,Jan Wehkamp,Charles L. Bevins,Walter Reinisch,Alexander Teml,Matthias Schwab,Peter Lichter,Bernhard Radlwimmer,Eduard F. Stange +12 more
TL;DR: It was shown that healthy individuals, as well as patients with ulcerative colitis, have a median of 4 HBD-2 gene copies per genome, which predisposes to colonic CD, most likely through diminished beta-defensin expression.
Journal ArticleDOI
NF-κB- and AP-1-Mediated Induction of Human Beta Defensin-2 in Intestinal Epithelial Cells by Escherichia coli Nissle 1917: a Novel Effect of a Probiotic Bacterium
Jan Wehkamp,Jürgen Harder,Kai Wehkamp,Birte Wehkamp-von Meissner,Miriam Schlee,Corinne Enders,Ulrich Sonnenborn,Sabine Nuding,Stig Bengmark,Klaus Fellermann,Jens-Michael Schröder,Eduard F. Stange +11 more
TL;DR: It is demonstrated that probiotic bacteria may stimulate the intestinal innate defense through the upregulation of inducible antimicrobial peptides such as hBD-2.
Journal Article
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Commentary
Klaus Herrlinger,Klaus Fellermann,Eduard F. Stange,Haruhiko Ogata,Toshiyuki Matsui,M. Nakamura,Mitsuo Iida,Masakazu Takazoe,Yasuo Suzuki,Toshifumi Hibi +9 more
TL;DR: The findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC and the optimal target range appears to be 10–15 ng/ml in terms of efficacy with two week therapy.